Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration. Current treatments, such as corticosteroids and rehabilitation, only slow disease progression without providing a cure. Gene therapy offers a promising alternative by directly addressing the genetic cause, with adeno-associated viruses (AAVs) being the most effective vectors due to their low toxicity, high stability and long-lasting transgene expression. But despite these advantages, there are also some limits. First, the size of the genome has to be lower than 4,7 kb due to the low capacity of the vector. To overcome this, researchers developed a shortened gene called micro-dystrophin which is small enough to fit inside the vector.